San Diego, CA, United States of America

Neil W Gibson

USPTO Granted Patents = 3 

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2016-2018

Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Neil W. Gibson in Metabolic Research

Introduction

Neil W. Gibson, an accomplished inventor based in San Diego, CA, has made significant strides in the field of metabolic disorders through his innovative research. With a total of three patents to his name, Gibson's work emphasizes the potential of modified oligonucleotides in treating various diseases.

Latest Patents

Gibson's latest patents focus on the therapeutic targeting of microRNAs to address metabolic disorders. He describes compounds that comprise modified oligonucleotides that are complementary to miR-103 and/or miR-107. These advancements present new methods for treating diseases and disorders linked to these crucial microRNAs.

Career Highlights

Throughout his career, Neil W. Gibson has been associated with Regulus Therapeutics Inc., a company that specializes in developing innovative RNA-targeted medicines. His work has not only contributed to advancing existing medical treatments but also paved the way for new approaches in molecular medicine.

Collaborations

Gibson collaborates with esteemed professionals in his field, including Balkrishen Bhat and Diedre MacKenna. These partnerships foster an environment of shared knowledge, enhancing research outcomes and driving innovative solutions in metabolic health.

Conclusion

Neil W. Gibson's contributions to the field of metabolic disorders showcase the impact of innovative inventions on healthcare. Through his patents and collaborations at Regulus Therapeutics Inc., Gibson continues to push the boundaries of scientific research, aiming to improve treatment modalities for metabolic conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…